Munich's hepatology services at LMU Klinikum and MRI Klinikum manage a significant Hepatitis B population, including patients from Eastern Europe, Asia, and the Middle East where HBV prevalence is higher. Tafsure offers Munich patients the most advanced TAF-based Hepatitis B treatment at significantly reduced cost compared to private German pharmacy pricing.
TAF's superior kidney and bone safety profile is particularly valuable in Munich's ageing population, where pre-existing kidney conditions and osteoporosis risk make the tolerability advantages over TDF clinically meaningful for long-term lifelong therapy.
❓ Can patients with fatty liver disease safely take Tafsure for Hepatitis B?
Yes — TAF-based Tafsure is considered safe and appropriate for patients with concurrent non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), which commonly co-exists with chronic Hepatitis B. In fact, treating HBV effectively with antivirals like Tafsure can reduce liver inflammation and fibrosis progression even in patients with fatty liver, since it removes the additional inflammatory burden the HBV infection adds to an already stressed liver. However, managing the fatty liver itself — through weight loss, diet, and treating metabolic risk factors like diabetes and high cholesterol — remains equally important for overall liver health alongside antiviral therapy.
